Bart Heeg

1.5k total citations
102 papers, 1.1k citations indexed

About

Bart Heeg is a scholar working on Hematology, Economics and Econometrics and Oncology. According to data from OpenAlex, Bart Heeg has authored 102 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Hematology, 26 papers in Economics and Econometrics and 24 papers in Oncology. Recurrent topics in Bart Heeg's work include Multiple Myeloma Research and Treatments (26 papers), Health Systems, Economic Evaluations, Quality of Life (24 papers) and Statistical Methods in Clinical Trials (15 papers). Bart Heeg is often cited by papers focused on Multiple Myeloma Research and Treatments (26 papers), Health Systems, Economic Evaluations, Quality of Life (24 papers) and Statistical Methods in Clinical Trials (15 papers). Bart Heeg collaborates with scholars based in United States, Germany and Netherlands. Bart Heeg's co-authors include Ben A. van Hout, Erik Buskens, Mahmoud Hashim, Ben van Hout, Maarten J. Postma, Annette Lam, Meletios Α. Dimopoulos, Margarita Kulakova, Frank de Charro and Jianming He and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Bart Heeg

90 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bart Heeg United States 19 370 342 303 273 192 102 1.1k
Safiya Abouzaid United States 16 405 1.1× 164 0.5× 262 0.9× 250 0.9× 92 0.5× 41 971
Amy Guo United States 18 413 1.1× 197 0.6× 130 0.4× 196 0.7× 46 0.2× 63 1.4k
Sabrina Trippoli Italy 17 149 0.4× 218 0.6× 68 0.2× 213 0.8× 65 0.3× 99 932
Francesco Cottone Italy 19 303 0.8× 195 0.6× 108 0.4× 334 1.2× 44 0.2× 60 1.1k
Ágnes Benedict United States 18 82 0.2× 418 1.2× 92 0.3× 283 1.0× 88 0.5× 57 1.2k
Kathleen Lang United States 16 79 0.2× 162 0.5× 79 0.3× 246 0.9× 67 0.3× 33 764
Andrea Denicoff United States 22 83 0.2× 248 0.7× 280 0.9× 801 2.9× 22 0.1× 69 1.5k
Hannah Bower Sweden 16 656 1.8× 95 0.3× 108 0.4× 295 1.1× 12 0.1× 42 1.3k
Michael J. Zoratti Canada 14 54 0.1× 118 0.3× 107 0.4× 89 0.3× 37 0.2× 40 773
D. Cohen United Kingdom 13 339 0.9× 46 0.1× 373 1.2× 216 0.8× 22 0.1× 48 1.4k

Countries citing papers authored by Bart Heeg

Since Specialization
Citations

This map shows the geographic impact of Bart Heeg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart Heeg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart Heeg more than expected).

Fields of papers citing papers by Bart Heeg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bart Heeg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart Heeg. The network helps show where Bart Heeg may publish in the future.

Co-authorship network of co-authors of Bart Heeg

This figure shows the co-authorship network connecting the top 25 collaborators of Bart Heeg. A scholar is included among the top collaborators of Bart Heeg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bart Heeg. Bart Heeg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Weisel, Katja, Meletios Α. Dimopoulos, Meral Beksaç, et al.. (2024). Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison. Leukemia & lymphoma. 65(4). 481–492. 3 indexed citations
2.
3.
Heeg, Bart, Gabriel Tremblay, Ofir Harari, et al.. (2023). Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity. Journal of Comparative Effectiveness Research. 12(3). e220159–e220159. 1 indexed citations
4.
Mazières, Julien, et al.. (2023). MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes. Clinical Lung Cancer. 24(6). 483–497. 33 indexed citations
5.
Mamolo, Carla, et al.. (2022). Efficacy of Non-Intensive Therapies Approved for Relapsed/Refractory Acute Myeloid Leukemia: A Systematic Literature Review. Future Oncology. 18(16). 2029–2039. 4 indexed citations
6.
Harari, Ofir, et al.. (2022). Network meta‐interpolation: Effect modification adjustment in network meta‐analysis using subgroup analyses. Research Synthesis Methods. 14(2). 211–233. 7 indexed citations
7.
Mamolo, Carla, et al.. (2021). Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting. Applied Health Economics and Health Policy. 19(6). 929–940. 3 indexed citations
8.
9.
Mamolo, Carla, et al.. (2021). An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia. Current Medical Research and Opinion. 37(5). 801–809. 7 indexed citations
10.
11.
12.
Cortes, Jörge E., Carla Mamolo, Joseph C. Cappelleri, et al.. (2019). Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia. Current Medical Research and Opinion. 35(9). 1615–1622. 12 indexed citations
13.
14.
15.
16.
17.
Chuang, Ling‐Hsiang, M. Treur, Bart Heeg, Ben van Hout, & Anna Filonenko. (2013). The use and impact of value of information analysis in decision-making. Value in Health. 16(3). A30–A30. 1 indexed citations
18.
Charokopou, M., Bart Heeg, & István Májer. (2012). RE1 Factors Influencing Drug Reimbursement Decision in Scotland. Value in Health. 15(7). A287–A287. 1 indexed citations
19.
Heeg, Bart, et al.. (2010). Cost Effectiveness of Long-Acting Risperidone in Sweden. Applied Health Economics and Health Policy. 8(5). 327–341. 19 indexed citations
20.
Chue, Pierre, Bart Heeg, Erik Buskens, & Ben A. van Hout. (2005). Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. PharmacoEconomics. 23(S1). 62–74. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Safiya Abouzaid Breakdown of academic impact, for papers by Amy Guo Breakdown of academic impact, for papers by Sabrina Trippoli Breakdown of academic impact, for papers by Francesco Cottone Breakdown of academic impact, for papers by Ágnes Benedict Breakdown of academic impact, for papers by Kathleen Lang Breakdown of academic impact, for papers by Andrea Denicoff Breakdown of academic impact, for papers by Hannah Bower Breakdown of academic impact, for papers by Michael J. Zoratti Breakdown of academic impact, for papers by D. Cohen
Rankless by CCL
2026